

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2636 8100 (20 Lines)
Fax : +91-79-2636 2368
www.zyduscadila.com
CIN:L24230GJ1935PLC025878

May 23, 2017

BSE Limited

1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: **Press Release**

Dear Sir / Madam,

We enclose herewith a copy of press release dated May 23, 2017 titled Zydus receives final approval from the USFDA for Cyproheptadine Hydrochloride tablets USP.


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY



Zydus receives final approval from the USFDA for Cyproheptadine Hydrochloride tablets USP

Ahmedabad, 23 May 2017

Zydus Cadila has received the final approval from the USFDA to market Cyproheptadine Hydrochloride Tablets USP, 4 mg. It is an antihistamine used to relieve allergy symptoms such as watery eyes, running nose, itching eyes or nose, sneezing, hives, and itching.

The drug will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has around 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
